Arcadia Biosciences appoints Kevin Comcowich to Interim CEO

Date:12-21-2021

Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief executive officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO. As previously announced on September 7, 2021, the board of directors launched a national search for a new CEO as the company further expands into the consumer packaged goods (CPG) sector.

Comcowich will continue to serve as board chair, a role he was appointed to in 2017. He joined the Arcadia board as an independent director in 2016 and previously served as chair of the audit committee.

“This is an exciting time for the company as we are in the final stages of our search for a permanent CEO to lead the company forward,” said Comcowich. “I’m energized by the impressive work that’s being done to build our portfolio of on-trend, plant-based food, beverage and body care products.”

Matthew Plavan, Arcadia’s CEO since 2019, will be departing the company as of December 31, 2021.